Active substanceTramadolTramadol
Similar drugsTo uncover
  • Tramadol
    capsules inwards 
    OZONE, LLC     Russia
  • Tramadol
    solution for injections 
  • Tramadol
    pills inwards 
    PRANAFARM, LLC     Russia
  • Tramadol
    pills inwards 
    OZONE, LLC     Russia
  • Tramadol
    solution for injections 
    Hemofarm AD     Serbia
  • Tramadol
    capsules inwards 
    Hemofarm AD     Serbia
  • Tramadol
    solution for injections 
  • Tramadol
    suppositories rect. 
    HEXAL AG     Germany
  • Tramadol
    solution for injections 
    HEXAL AG     Germany
  • Tramadol
    pills inwards 
    HEXAL AG     Germany
  • Tramadol
    capsules inwards 
    HEXAL AG     Germany
  • Tramadol
    solution for injections 
  • Tramadol
    pills inwards 
    ORGANICS, JSC     Russia
  • Tramadol
    solution for injections 
    ORGANICS, JSC     Russia
  • Tramadol
    solution for injections 
    BRYNTSALOV-A, CJSC     Russia
  • Tramadol
    capsules inwards 
  • Tramadol
    drops inwards 
  • Tramadol
    suppositories rect. 
  • Tramadol retard
    pills inwards 
  • Tramadol STADA®
    capsules inwards 
  • Tramadol-Acry®
    capsules inwards 
    AKRIKHIN HFK, JSC     Russia
  • Tramadol-GR
    solution for injections 
  • Tramadol-GR
    solution for injections 
  • Tramadol-Plekhiko
    solution for injections 
  • Tramaclosydol®
    pills inwards 
    Laboratorios Bago S.A.     Argentina
  • Tramaclosydol®
    solution for injections 
    Laboratorios Bago S.A.     Argentina
  • Tramal®
    solution for injections 
  • Tramal®
    suppositories rect. 
  • Tramal®
    drops inwards 
    Grünenthal GmbH     Germany
  • Tramal®
    capsules inwards 
  • Tramal®ardard
    pills inwards 
  • Tramolin®
    solution for injections 
    BRYNTSALOV-A, CJSC     Russia
  • Dosage form: & nbsp

    capsules

    Composition:

    One capsule contains:

    Active substance: tramadol hydrochloride 50 mg;

    Excipients: cellulose microcrystalline 28 mg, sodium carboxymethyl starch (type A) 20 mg, silicon dioxide colloid 2 mg, magnesium stearate 5 mg;

    ABOUTbolus capsule (capsule case / capsule cover): iron oxide yellow (E172) 0.175 mg (0.091 / 0.084 mg), indigocarmine (E132) 0.012 mg (- / 0.012 mg), titanium dioxide (E171) 0.557 mg (0.456 / 0.101 mg), gelatin 37.180 mg (22.223 / 14.957 mg ), sodium lauryl sulfate 0.076 mg (0.030 / 0.046 mg), Capsugel 1028 black ink (shellac 47.5% (22% esterified) in ethanol denatured 74 EP, iron oxide black (E172), propylene glycol (E1520), ethanol denatured 74 OP), about 150 mg per 1000 capsules.

    Description:Solid gelatin capsules of the elongated form No. 4, consisting of a light yellow opaque body and a green opaque lid, shiny, with a Snap fit closure (Coni-Snap®). The logo of the Grünenthal company is printed on the cap and body. Contents of the capsule: fine powder from white to light yellow color, odorless.
    Pharmacotherapeutic group:An analgesic with a mixed mechanism of action.
    ATX: & nbsp

    N.02.A.X.02   Tramadol

    Pharmacodynamics:
    Tramadol is an opioid analgesic with a central mechanism of action. It is a nonselective complete agonist of μ-, δ- and k-opioid receptors with a high affinity for μ-receptors. The second mechanism of action of tramadol, which enhances its analgesic effect, is suppression of norepinephrine reuptake by neurons and increased release of serotonin.
    Tramadol has antitussive action. In contrast to morphine, in therapeutic doses does not depress respiration and to a lesser extent affect intestinal motility. Influence on the cardiovascular system is weakly expressed. The analgesic potential of tramadol is 1/10 - 1/6 of the activity of morphine.
    Pharmacokinetics:When taking capsules, absorption is more than 90%. The average absolute bioavailability is about 70% regardless of the intake of food. The decrease in bioavailability to 70% is due to the effect of "first passage" through the liver. In comparison with other opioid analgesics, the absolute bioavailability of Tramal® is extremely high. After oral administration of 100 mg of tramadol in the form of capsules by young healthy volunteers, the maximum concentration in the blood plasma (Cmax) is 208-280 μg / l, the time to reach Cmax 1.6-2 hours.
    Binding to plasma proteins is about 20%. Penetrates through blood-brain and placental barriers. Insignificant amounts of tramadol and its demethylated derivative (0.1% and 0.02%, respectively) are excreted in breast milk. In the metabolism of tramadol, the isozymes CYP3A4 and CYP2D6 are involved, the suppression of these isoenzymes by other substances can affect the concentration of tramadol and its active metabolite in the blood.To date, clinically significant interactions with other drugs mediated by this mechanism have not been identified. Tramadol and its metabolites are excreted mainly in the urine, the average cumulative index of renal excretion is 90%.
    The half-life of tramadol (T1 / 2) is approximately 6 hours, regardless of the route of administration. In patients older than 75 years, the elimination half-life can be increased by a factor of 1.4; with cirrhosis of the liver to 13.3 ± 4.9 h (tramadol), 18.5 ± 9.4 h (O-demethyltramadol), in severe cases - 22.3 h and 36 h respectively. T1 / 2 with renal insufficiency (creatinine clearance less than 5 ml / min) - 11 ± 3.2 h (tramadol), 16.9 ± 3 h (O-demethyltramadol), in severe cases - 19.5 h and 43.2 h respectively.
    In the liver, it is metabolized by N- and O-demethylation followed by conjugation with glucuronic acid. Only O-demethyltramadol has pharmacological activity. There are significant individual differences in the concentration of other metabolites. 11 metabolites of tramadol were found in urine.
    In therapeutic doses tramadol has a linear pharmacokinetic profile. The ratio of the concentration of tramadol in the blood serum and the analgesic effect is dose-dependent,varying in individual individuals. The concentration of tramadol in the blood serum of 100-300 ng / ml is usually effective.
    Indications:Pain syndrome of medium and high intensity of various etiologies (for example, pain in cancer patients, in trauma and in the postoperative period).
    Contraindications:
    - hypersensitivity to tramadol or any of the components of the drug;
    - acute intoxication with alcohol, hypnotics, analgesics, opioids or other psychotropic drugs;
    - contraindicated the joint use of tramadol with monoamine oxidase (MAO) inhibitors, and also within 14 days after the end of their admission;
    - epilepsy, not amenable to adequate drug control;
    - contraindicated the use of tramadol as a drug for the treatment of the syndrome of "withdrawal" of drugs;
    - contraindicated during pregnancy. During breastfeeding the drug can be prescribed only for vital indications. In the case of a single dose, there is no need to interrupt breastfeeding;
    - it is contraindicated the administration of Tramal® in capsules to children under 14 years of age.
    Carefully:
    Tramadol should be used with caution:
    - in patients with opioid dependence;
    - with craniocerebral trauma, in patients with shock, in patients with impaired consciousness of unclear genesis, in patients with respiratory distress and disruption of the respiratory center, with increased intracranial pressure;
    - the drug should be used with caution in patients with established severe intolerance to opioids of allergic and non-allergic genesis;
    - with epilepsy, amenable to adequate drug control, or in patients prone to developing seizures, tramadol can only be used for life indications (see "Special instructions");
    - In patients with a tendency to abuse drugs or drug dependence, tramadol should be treated with short courses and under medical supervision (see "Special instructions"),
    Pregnancy and lactation:Tramadol penetrates the placental barrier. Convincing evidence of the safety of the use of tramadol during pregnancy in humans is not obtained, therefore tramadol Do not use during pregnancy.Long-term use of tramadol during pregnancy can lead to the development of symptoms of "cancellation" in a newborn. Tramadol does not affect the contractility of the uterus during childbirth. In newborns tramadol can cause a change in the frequency of respiration, which is usually not clinically relevant. About 0.1% of the dose of tramadol administered to the mother is excreted with milk during lactation. Tramadol should not be used during pregnancy and lactation. After a single dose of tramadol, there is usually no need to interrupt breastfeeding.
    Dosing and Administration:

    Tramal® capsules should be taken orally. Capsules Tramal® are swallowed whole, without chewing and not opening, with a sufficient amount of liquid, regardless of food intake.

    The dose should be selected individually, depending on the intensity of the pain syndrome and the individual sensitivity of the patient. The recommended doses are indicative. The duration of treatment with the drug is determined individually. In the treatment it is always necessary to select the minimum effective dose of the drug. In the treatment of chronic pain syndrome should adhere to a specific schedule for taking the drug.

    Do not exceed the daily dose of tramadol - 400 mg, except in special circumstances (for example, oncological pain or severe postoperative pain).

    Adults and adolescents over 14 years of age.

    A single dose of 50 mg of tramadol. In the case of an insufficient analgesic effect, after 50-60 minutes, 50 mg of tramadol is taken again. With intensive pain, the recommended single dose of 100 mg of tramadol.

    Depending on the intensity of the pain syndrome, the analgesic effect is usually maintained during 4-6 hours. In the postoperative period, short-term administration of higher doses of Tramal® in the early periods after surgery is possible.

    Patients of advanced age.

    In elderly patients (up to 75 years old) without clinical manifestations of hepatic or renal failure, a dose change of tramadol is usually not required. In patients older than 75 years, excretion may slow down. Therefore, if it seems necessary, the break between the drug intake can be increased according to the patient's condition.

    Patients with renal insufficiency or on dialysis and patients with hepatic insufficiency.

    If the renal and / or liver function is impaired, the excretion of tramadol from the body is slowed. If necessary, the interval between doses of the drug should be increased.

    Duration of therapy.

    Tramadol should never be used for longer than necessary. With long-term use of tramadol, due to the intensity or etiology of the pain syndrome, periodic monitoring (if necessary with interruptions in taking the drug) is necessary to determine the need for further therapy and dose optimization.

    Side effects:

    The most common side effects are nausea and dizziness, noted in more than 10% of patients.

    The frequency is defined as follows:

    Often: >1/10;

    Often: >1/100, <1/10;

    Infrequently: >1/1000, <1/100;

    Rarely: >1/10 000, <1/1000;

    Very rarely: <1/10 000;

    Insufficient data: can not be determined based on available data.

    From the cardiovascular system:

    Infrequent: effects on cardiovascular regulation (palpitations, tachycardia, orthostatic hypotension or collapse). These side effects are mainly observed with intravenous administration of the drug or with significant physical exertion.

    Rarely: bradycardia, increased blood pressure.

    Disorders from the metabolism and nutrition:

    Rarely: changes in appetite.

    From the respiratory system: Rarely: respiratory depression, shortness of breath.

    At a significant excess of the recommended doses with simultaneous use of other drugs that depress the central nervous system (CNS), respiratory depression is possible.

    There was a deterioration in bronchial asthma, but the cause-

    the investigational link with the use of the drug was not established.

    Impaired nervous system:

    Very often: dizziness.

    Often: headache, drowsiness.

    Rarely: speech disorders, paresthesia, tremor, epileptiform seizures, involuntary muscle contractions, coordination disorders, fainting.

    Epileptiform seizures are possible after applying high doses of tramadol and with simultaneous use with drugs that lower the threshold of convulsive readiness.

    Disorders of the psyche:

    Rarely: hallucinations, confusion, sleep disturbances, anxiety, delirium and nightmares. After the use of tramadol, various rarely observed undesirable reactions from the psyche are possible (depending on the personality characteristics of the patient and the duration of treatment).These side effects include mood changes (usually euphoria, sometimes dysphoria), changes in activity (usually a decrease, sometimes an increase), impairment of cognitive functions and perception (eg, decision-making, perceptual disorders). Perhaps the development of drug dependence.

    From the side of the organ of vision:

    Rarely: miosis, mydriasis, blurred vision.

    On the part of the digestive system:

    Very often: nausea.

    Often: constipation, dry mouth, vomiting.

    Infrequent: vomiting, a feeling of heaviness in the epigastrium, flatulence, diarrhea.

    From the skin and subcutaneous tissue:

    Often: sweating.

    Infrequent: itching, rash, hives.

    From the musculoskeletal system:

    Rarely: muscle weakness.

    From the liver and bile ducts:

    In a few isolated cases, an increase in the activity of liver enzymes

    time coinciding with therapy with tramadol.

    From the side of the kidneys and the urinary system:

    Rarely: disturbances of urination (dysuria and urinary retention).

    Immune system disorders:

    Rarely: allergic reactions (dyspnea, bronchospasm, wheezing, angioedema) and anaphylaxis.

    General disorders:

    Often: fatigue.

    Rarely: the possible symptoms of "cancellation" are similar to the symptoms of "withdrawal" of opioids: agitation, anxiety, nervousness, sleep disorders, hyperkinesia, tremor and gastrointestinal symptoms. Other symptoms that are very rare with tramadol cancellation include panic attacks, severe anxiety, hallucinations, paresthesia, ringing in the ears and other extremely rare CNS symptoms (confusion, hallucinations, depersonalization, derealization, paranoia).

    If any of the following side effects occur, or if there are other side effects not indicated in the instructions, tell your doctor.

    Overdose:

    In case of an overdose of tramadol, symptoms characteristic of opioid analgesics of the central action should be expected.

    Possible Symptoms: miosis, vomiting, collapse, consciousness up to coma, convulsions, depression of the respiratory center to apnea.

    Treatment: Providing airway patency. Maintain respiration and cardiovascular activity depending on the symptomatology. If breathing is disturbed, enter naloxone. When convulsions should be administered intravenously diazepam. When an overdose of the drug in oral dosage forms, it is necessary to wash the stomach and prescribe Activated carbon within the first two hours after an overdose. After taking especially large doses of the drug in capsules, removal of the contents of the stomach can be effective and at a later date. Hemodialysis and hemofiltration are ineffective in overdose.

    Interaction:
    Tramadol can not be administered simultaneously or within 14 days after the abolition of monoamine oxidase inhibitors (MAO). In patients treated with MAO inhibitors, life-threatening drug interactions, manifested by symptoms from the central nervous system, respiratory and cardiovascular systems, were noted 14 days before the start of the use of the opioid analgesic pethidine. Similar interactions with MAO inhibitors are possible with the administration of tramadol. The simultaneous use of tramadol and substances that suppress the activity of the central nervous system, including alcohol, can increase the side effects of the central nervous system. It is noted that with the joint or previous use of cimetidine (an inhibitor of microsomal liver enzymes) clinically significant interactions are unlikely.The simultaneous or previous use of carbamazepine (an inductor of microsomal liver enzymes) can reduce the analgesic effect of tramadol and shorten its duration.
    Tramadol can cause seizures and increase the effect of selective serotonin reuptake inhibitors (SSRIs), serotonin-noradrenaline reuptake inhibitors (SSRIs), tricyclic antidepressants, antipsychotics and other drugs that lower the seizure threshold (for example, bupropion, mirtazapine), thus leading to the development of seizures.
    Simultaneous use of tramadol with other serotonergic drugs, such as selective serotonin reuptake inhibitors (SSRIs), serotonin-noradrenaline reuptake inhibitors (SSRIs), MAO inhibitors, tricyclic antidepressants and mirtazapine can lead to the development of serotonin syndrome. Possible symptoms of serotonin syndrome: confusion, agitation, hyperthermia, sweating, ataxia, hyperreflexia, myoclonus and diarrhea. The abolition of serotonergic drugs causes rapid disappearance of symptoms.The necessary therapy is determined by the clinical picture and the severity of the symptoms. With the simultaneous use of tramadol and coumarin derivatives (eg warfarin), careful monitoring of patients is necessary, as some have an increase in the international normalized ratio (MHO) with the development of bleeding and ecchymosis.
    Other inhibitors of the isoenzyme CYP3A4, for example, ketoconazole and erythromycin, can slow down the metabolism of tramadol (N-demethylation) and, possibly, active O-demethyltramadol. The clinical significance of this interaction has not been studied. There is limited evidence that pre- or post-operative use of the 5-HTs receptor blocker-ondansetron has increased the need for tramadol in patients with postoperative pain syndrome.

    Special instructions:
    In patients with opioid dependence, head trauma, shock, in patients with impaired consciousness of unclear etiology, breathing disorders or respiratory center damage, increased intracranial pressure tramadol should only be used with extreme caution.
    The drug should be used with caution in patients with known cases of severe intolerance to opioids of allergic and non-allergic origin.
    There have been cases of seizures in patients taking tramadol in recommended doses. The risk of seizures may increase if the recommended maximum daily dose of the drug is exceeded (400 mg). The administration of tramadol may increase the risk of seizures in patients taking drugs that reduce the convulsive threshold. Patients with epilepsy and patients prone to developing seizures should take tramadol only for life indications.
    Tramal® has a low potential for drug dependence. However, with prolonged use, addiction, physical and mental dependence are possible. In patients prone to drug abuse, or to the development of drug dependence, treatment with Tramal® should only be carried out with short courses and under medical supervision.
    Tramal® is not applicable as a substitute therapy for patients with opioid dependence. Although tramadol is an agonist of opioid receptors, it can not suppress the symptoms of "withdrawal" of morphine.
    Effect on the ability to drive transp. cf. and fur:Even at recommended doses tramadol can cause effects such as drowsiness and dizziness and can therefore disrupt the reaction of car drivers and machine operators. When taking Tramal® it is necessary to refrain from driving and practicing potentially dangerous activities that require increased concentration of attention and rapid psychomotor reactions, especially when combined with other psychotropic drugs or alcohol.
    Form release / dosage:Capsules 50 mg.
    Packaging:10 capsules in a blister of a film of polypropylene or polyvinyl chloride / polyvinylidene chloride and aluminum foil. 2 blisters together with instructions for use in a pack of cardboard.
    Storage conditions:At a temperature of no higher than 25 ° C. Keep out of the reach of children.
    Shelf life:5 years. Do not use after the expiration date indicated on the package.
    Terms of leave from pharmacies:On prescription
    Registration number:П N014289 / 01
    Date of registration:21.11.2008
    Date of cancellation:2017-09-26
    The owner of the registration certificate:SHTADA Artznajmittel AGSHTADA Artznajmittel AG Germany
    Manufacturer: & nbsp
    Representation: & nbspSTADA CISASTADA CISARussia
    Information update date: & nbsp26.09.2017
    Illustrated instructions
      Instructions
      Up